Randomized phase III studies have now shown that treatment combining antiangiogenics with a PD-(L)1 antibody significantly increased survival compared to standard-of-care treatment in RCC, NSCLC, and HCC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.